Prosecution Insights
Last updated: April 19, 2026
Application No. 18/373,005

SELECTIVELY DISPLAYING FILTERED PHYSIOLOGICAL PARAMETERS

Non-Final OA §102
Filed
Sep 26, 2023
Examiner
D ABREU, MICHAEL JOSEPH
Art Unit
3796
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Stryker Corporation
OA Round
1 (Non-Final)
67%
Grant Probability
Favorable
1-2
OA Rounds
4y 5m
To Grant
89%
With Interview

Examiner Intelligence

Grants 67% — above average
67%
Career Allow Rate
462 granted / 694 resolved
-3.4% vs TC avg
Strong +23% interview lift
Without
With
+22.6%
Interview Lift
resolved cases with interview
Typical timeline
4y 5m
Avg Prosecution
72 currently pending
Career history
766
Total Applications
across all art units

Statute-Specific Performance

§101
8.3%
-31.7% vs TC avg
§103
40.8%
+0.8% vs TC avg
§102
30.4%
-9.6% vs TC avg
§112
17.0%
-23.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 694 resolved cases

Office Action

§102
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Applicant’s election without traverse of Group II, Claims 4-13, in the reply filed on 24 November 2025 is acknowledged. Claims 1-3 and 14-20 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention/group, there being no allowable generic or linking claim. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale or otherwise available to the public before the effective filing date of the claimed invention. (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claims 4-13 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Sullivan et al. (US 2021/0015387; hereinafter “Sullivan”). Regarding claim 4, Sullivan teaches a method performed by a first medical device, the method comprising: detecting an analog signal indicating a physiological parameter of a subject (e.g. ¶¶ 369 – ECG leads measure analog signals); converting the analog signal to first data (e.g. ¶¶ 202-204 – where the analog data is converted for filtering and then visual display); determining a treatment parameter characterizing a treatment administered to the subject by a second medical device (e.g. ¶¶ 84 – where chest compressions are the treatment considered delivered); generating a filter characterized by the treatment parameter and generating second data by applying the filter to the first data (e.g. ¶¶ 69 - structured to filter the ECG signal, e.g., apply at least one filter to the signal so as to remove chest compression artifacts resulting from chest compressions being delivered to the person 82.” – where the treatment parameter would be chest compressions); and displaying, on a user interface, the first data and the second data, wherein the second data is emphasized on the user interface (e.g. ¶¶ 202 – “colorimetric scale” – where the examiner notes the colors are used to emphasize scaling and importance). Regarding claim 5, Sullivan teaches the physiological parameter comprises an electrocardiogram (ECG), a capnograph, a transthoracic impedance, a force administered to a user, a blood pressure, an airway parameter, a partial pressure of oxygen, an electroencephalogram (EEG), a temperature, a blood flow, or a pulse rate (e.g. ¶¶ 69 - ECG). Regarding claim 6, Sullivan teaches determining the treatment parameter comprises: determining, by analyzing the first data, a frequency of the treatment (e.g. ¶¶ 86). Regarding claim 7, Sullivan teaches the treatment parameter comprises: receiving, from the second medical device, a signal indicating the treatment parameter (e.g. ¶¶ 86 – chest compression frequency). Regarding claim 8, Sullivan teaches determining that the second data is more reliable than the first data (e.g. ¶¶ 97 – RMS value is “a reliable indicator of chest compressions”). Regarding claim 9, Sullivan teaches displaying the first data and the second data comprises overlaying and time-aligning the first data and the second data on the user interface (e.g. ¶¶ 170). Regarding claim 10, Sullivan teaches displaying the first data and the second data comprises: displaying a first waveform representing the first data; and displaying a second waveform representing the second data (e.g. ¶¶ 200-205). Regarding claim 11, Sullivan teaches the first waveform comprises a different color than the second waveform, the first waveform comprises a different contrast than the second waveform, the first waveform comprises a different line size than the second waveform, the first waveform comprises a different transparency than the second waveform, or the first waveform comprises a different line style than the second waveform (e.g. Fig 8 - data/time). Regarding claim 12, Sullivan teaches the physiological parameter comprising a first physiological parameter, the method further comprising: detecting a second physiological parameter of the subject; generating third data indicative of the second physiological parameter; and displaying, on the user interface, a waveform representing the third data (e.g. Fig. 16). Regarding claim 13, Sullivan teaches detecting, by analyzing the first data or the second data, an event indicative of the treatment; and displaying, on the user interface, a symbol indicating the event (e.g. Figs. 23-24 – with in graph indications). Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michael D’Abreu whose telephone number is (571) 270-3816. The examiner can normally be reached on 7AM-4PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, David Hamaoui can be reached at (571) 270-5625. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /MICHAEL J D'ABREU/Primary Examiner, Art Unit 3796
Read full office action

Prosecution Timeline

Sep 26, 2023
Application Filed
Dec 13, 2025
Non-Final Rejection — §102
Apr 16, 2026
Examiner Interview Summary
Apr 16, 2026
Applicant Interview (Telephonic)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12575755
DETERMINING HEALTH CONDITION STATUSES USING SUBCUTANEOUS IMPEDANCE MEASUREMENTS
2y 5m to grant Granted Mar 17, 2026
Patent 12546320
BLOOD PUMP WITH MICROMOTOR
2y 5m to grant Granted Feb 10, 2026
Patent 12527948
FLUID HANDLING SYSTEM
2y 5m to grant Granted Jan 20, 2026
Patent 12521546
BLOOD PUMP
2y 5m to grant Granted Jan 13, 2026
Patent 12507940
LAYERED MULTI-ACTIVATION LOCAL ACTIVATION TIMES (LAT) MAPPING
2y 5m to grant Granted Dec 30, 2025
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
67%
Grant Probability
89%
With Interview (+22.6%)
4y 5m
Median Time to Grant
Low
PTA Risk
Based on 694 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month